Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

In a lawsuit filed in Delaware Chancery Court, Pfizer said Novo Nordisk’s offer can’t be considered superior because it isn’t ...

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US ...

Trump's remark, made during a White House event on drug pricing, instantly turned Novo Nordisk into a lightning rod for the administration's push to lower costs. The company confirmed discussions with ...

(Reuters) -Pfizer on Friday filed a lawsuit against Metsera and Novo Nordisk, accusing them of breaking a merger agreement ...

Viking Therapeutics is nearing the finish line with a candidate for weight loss -- to potentially enter a drug market that’s approaching $100 billion. This biotech has candidates in phase 2 and phase ...

(Reuters) -Several pharmaceutical companies have said they will sell drugs direct to patients in the U.S. and offered discounts following President Donald Trump's calls to bring down drug prices and ...

NVO trades at a rare dislocation with a forward P/E ~15% below sector and EPS growth ~66% above, primed for the 2026 healthcare re-rating. Its semaglutide engine (Wegovy growth, CagriSema pipeline, ...

Novo Nordisk is one of Europe’s largest companies and a global leader in the treatment of two major lifestyle diseases – diabetes and obesity. NVO repeatedly lowered its revenue and earnings growth ...